<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099046</url>
  </required_header>
  <id_info>
    <org_study_id>yk19700512</org_study_id>
    <nct_id>NCT01099046</nct_id>
  </id_info>
  <brief_title>Stress Management Therapy for Meniere's Disease</brief_title>
  <acronym>SMT</acronym>
  <official_title>Reduction of Plasma Vasopressin Level in Patients With Meniere's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osaka University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Attacks in Meniere's disease, characterized by vertigo and hearing loss, are well known to
      occur repeatedly under stressed environment. Hitherto, its pathology was revealed to be inner
      ear hydrops through human temporal bone studies in 1938. For the pathogenesis of inner ear
      hydrops resulting in Meniere's attacks, plasma vasopressin elevation due to stress and V2
      receptor overexpression in the inner ear could be essential as a basis of this disease. In
      the present study, we'd like to find the effective and feasible way to reduce plasma
      vasopressin level in patients with Meniere's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      For the pathogenesis of inner ear hydrops resulting in Meniere's attacks, plasma vasopressin
      elevation due to stress and V2 receptor overexpression in the inner ear could be essential as
      a basis of this disease. In the present study, we'd like to find the effective and feasible
      way to reduce plasma vasopressin level in patients with Meniere's disease.

      METHODS:

      We estimate to enroll 200 Meniere's patients to four study groups in a randomized controlled
      trial at Osaka University Hospital during this study period 2010-2015. Patients are diagnosed
      as Meniere's patients according to the 1995 AAO-HNS criteria. Group-I consists of 50 patients
      who receive just traditional oral intake medication including anti-diuretics. Group-II
      consists of 50 patients who receive both medication and water intake (at least 2.0 litters
      per day). Group-III consists of 50 patients who receive both medication and tympanic tubing
      (under local anesthesia). Group-IV consists of 50 patients who receive both medication and
      sleep well (regular sleep program under dark everynight). Additional factors to medication in
      each group are supposed to have influence on hypothalamus. We follow up all these patients at
      least 12 months and evaluate stress, psychological and dizziness conditions using a couple of
      questionnaires. We also examine changes in plasma vasopressin level of patients in each
      group.

      ESTIMATED RESULTS:

      Through this study, we can understand the most effective and feasible way to reduce plasma
      vasopressin level in patients with Meniere's disease. Much more Meniere's patients may be
      rescued without invasive surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Meniere's Disease</condition>
  <condition>Stress</condition>
  <arm_group>
    <arm_group_label>medication only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>medication = anti-diuretics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medication + water intake</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>anti-diuretics + water intake (at least 2.0 litters per day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medication + tympanic tubing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>anti-diuretics + tympanic tubing (under local anesthesia)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medication + regular sleep</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>anti-diuretics + regular sleep (regular sleep program under dark everynight)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle</intervention_name>
    <description>water intake, tympanic tubing, regular sleep</description>
    <arm_group_label>medication only</arm_group_label>
    <arm_group_label>medication + water intake</arm_group_label>
    <arm_group_label>medication + tympanic tubing</arm_group_label>
    <arm_group_label>medication + regular sleep</arm_group_label>
    <other_name>Stress Management Therapy (SMT)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed as Meniere's patients according to the 1995 AAO-HNS criteria are
             included into this study.

        Exclusion Criteria:

          -  Patients refused our prepared four kinds of treatments are excluded from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tadashi Kitahara, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Otolaryngology, Osaka University, School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tadashi Kitahara, M.D.,Ph.D.</last_name>
    <phone>+81-6-6879-3951</phone>
    <phone_ext>3951</phone_ext>
    <email>tkitahara@ent.med.osaka-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arata Horii, M.D.,Ph.D.</last_name>
    <phone>+81-6-6879-3954</phone>
    <phone_ext>3954</phone_ext>
    <email>ahorii@ent.med.osaka-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Otolaryngology, Osaka University, School of Medicine</name>
      <address>
        <city>Suita-city</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tadashi Kitahara, M.D.,Ph.D.</last_name>
      <phone>+81-6-6879-3951</phone>
      <phone_ext>3951</phone_ext>
      <email>tkitahara@ent.med.osaka-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Arata Horii, M.D.,Ph.D.</last_name>
      <phone>+81-6-6879-3954</phone>
      <phone_ext>3954</phone_ext>
      <email>ahorii@ent.med.osaka-u.ac.jp</email>
    </contact_backup>
    <investigator>
      <last_name>Tadashi Kitahara, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Takao Imai, M.D.,Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Kitahara T, Maekawa C, Kizawa K, Horii A, Doi K. Plasma vasopressin and V2 receptor in the endolymphatic sac in patients with delayed endolymphatic hydrops. Otol Neurotol. 2009 Sep;30(6):812-9. doi: 10.1097/MAO.0b013e3181b11db5.</citation>
    <PMID>19638944</PMID>
  </reference>
  <reference>
    <citation>Kitahara T, Doi K, Maekawa C, Kizawa K, Horii A, Kubo T, Kiyama H. Meniere's attacks occur in the inner ear with excessive vasopressin type-2 receptors. J Neuroendocrinol. 2008 Dec;20(12):1295-300. doi: 10.1111/j.1365-2826.2008.01792.x.</citation>
    <PMID>19094077</PMID>
  </reference>
  <reference>
    <citation>Kitahara T, Kubo T, Okumura S, Kitahara M. Effects of endolymphatic sac drainage with steroids for intractable Meniere's disease: a long-term follow-up and randomized controlled study. Laryngoscope. 2008 May;118(5):854-61. doi: 10.1097/MLG.0b013e3181651c4a.</citation>
    <PMID>18520184</PMID>
  </reference>
  <reference>
    <citation>Horii A, Uno A, Kitahara T, Mitani K, Masumura C, Kizawa K, Kubo T. Effects of fluvoxamine on anxiety, depression, and subjective handicaps of chronic dizziness patients with or without neuro-otologic diseases. J Vestib Res. 2007;17(1):1-8.</citation>
    <PMID>18219099</PMID>
  </reference>
  <reference>
    <citation>Horii A, Kitahara T, Uno A, Kondoh K, Morihana T, Okumura S, Nakagawa A, Mitani K, Masumura C, Kubo T. Vestibular function and vasopressin. Acta Otolaryngol Suppl. 2004 Aug;(553):50-3.</citation>
    <PMID>15277036</PMID>
  </reference>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2009</study_first_submitted>
  <study_first_submitted_qc>April 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2010</study_first_posted>
  <last_update_submitted>April 3, 2010</last_update_submitted>
  <last_update_submitted_qc>April 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Tadashi Kitahara / Associate Professor</name_title>
    <organization>Department of Otolaryngology &amp; Head and Neck Surgery, Osaka University School of Medicine</organization>
  </responsible_party>
  <keyword>Meniere's disease</keyword>
  <keyword>stress management</keyword>
  <keyword>vasopressin</keyword>
  <keyword>V2 receptor</keyword>
  <keyword>water intake</keyword>
  <keyword>tympanic tubing</keyword>
  <keyword>regular sleep under dark</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meniere Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 16, 2015</submitted>
    <returned>August 10, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

